Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11369493 | 0.85 | GAPDH (0.51) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5886845 | 0.85 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL5743296 | 0.77 | CYP3A4 (0.55) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4009384 | 0.77 | MAP2K4 (0.46) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4008802 | 0.77 | HSD17B10 (0.45) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4807576 | 0.77 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6482119 | 0.76 | ALDH1A1 (0.64) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6389467 | 0.76 | KMT2A (0.37) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL459934 | 0.76 | CA12 (0.44) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL746722 | 0.75 | ALDH1A1 (0.56) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0414299-B1 | Biocidal azoxime compounds | SHELL INT RESEARCH (NL) | 1994-06-15 | — | — | EP | claimed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
| EP-0757039-A1 | Endothelin receptor antagonists | MERCK PATENT GmbH (DE) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | MAPT 2577/4885ALDH1A1 1572/4885NPC1 1831/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | MAPT 4745/4885ALDH1A1 1501/4885NPC1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.